Sanders Corazon (Corsee) D. reported grant involving 6,000 derivative units of Calidi Biotherapeutics, Inc. at $0.00 for $0 on Aug 17, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Aug 19, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
6,000Non-Qualified Stock Options (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
6,000Direct
Trade date
Aug 17, 2026Grant
Filed
Aug 19, 2026, 7:00 PM ET2-day reporting delay
Accession
0001493152-26-039285Code A · Transaction 12139
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CLDI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CLDI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −92%1w ago +18%1d ago +15%
Returns since7d −2.2%30d −20%90d180d1y

Footnotes in full

F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F2: Does not include the stock options previously granted to the Reporting Person.